FDA grants Syndax breast cancer drug entinostat 'breakthrough' status

Syndax Pharmaceuticals revealed on 11 September the US FDA had granted breakthrough therapy designation to the company's experimental breast cancer drug entinostat, an experimental histone deacetylase inhibitor.